MFN News Items | Nanologica

Nanologica’s Nomination Committee Proposes Thomas Eldered as New Board Member of Nanologica AB

13 April, 2021

Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the Board of Directors to be elected at the Annual General Meeting on May 27. Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute ofTechnology and is the co-founder of Recipharm AB, where he was also the CEO from 2008–2021.Before that, Thomas was the Vice President of Recip

Nanologica Announces Date Change for Interim Reports for First and Second Quarter

30 March, 2021

Nanologica AB (publ) has changed the previously disclosed publication date of May 7, 2021 for the Company’s interim report for the first quarter 2021 to April 23, 2021. In addition, the date for the interim report for the second quarter 2021 has been changed from August 27, 2021 to July 9, 2021. Financial calendar 2021 Interim report January-March 2021 April 23, 2021 Annual

Nanologica ändrar datum för publicering av delårsrapporter

30 March, 2021

Nanologica AB (publ) har ändrat datum för publicering av bolagets delårsrapport för första kvartalet 2021 från den 7 maj till den 23 april. Utöver detta har bolaget ändrat datum för publicering av delårsrapport för andra kvartalet 2021 frånden 27 augusti till den 9 juli. Finansiell kalender 2021Delårsrapport januari-mars 2021 23 april, 2021Årsredovisning 2020 23 april, 2021Delårsrapport januari-juni 2021 9 juli, 2021Delårsrapport januari-september 2021 29 oktober, 2021 För ytterligare information, vänligen kontakta:Johanna Johansson, IR NanologicaTel: +46

Nanologica Announces Date Change for Interim Reports for First and Second Quarter

30 March, 2021

Nanologica to Attend BIO-Europe Spring March 22-25 for Partnering Discussions

10 March, 2021

Nanologica will be attending BIO-Europe Spring, March 22-25, to meet with potential pharmaceutical partners regarding drug delivery applications using NLAB Spiro[®] and NLAB Silica™. Nanologica’s drug delivery platforms NLAB Spiro® and NLAB Silica™ consists of nanoporous particles where APIs can be placed inside the pores. By loading the API into the particles, Nanologica can overcome several of the challenges that prevent or limit effective treatment of many serious diseases. Some of the technical benefits of

Year-End Report Nanologica 2020

26 February, 2021

SUMMARY OF THE PERIOD FINANCIAL OVERVIEW Net revenue increased by 75 percent to TSEK 16 135 (9 227) in total, of which the fourth quarter TSEK 6 071 (2 731) The operating result for the period was TSEK -19 571 (-20 066), of which the fourth quarter TSEK -3 648 (-6 260) Loss for the period was TSEK -22 199 (-21 080), of which the fourth quarter TSEK -5 427 (-6 855) Loss per share for the period was

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.